The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Platinum-based chemotherapy (chemo) with CS1001, an anti-PD-L1 antibody, for first-line advanced non-small cell lung cancer (NSCLC): Preliminary results from phase Ib cohorts of CS1001-101 study.
 
Qing Zhou
Honoraria - AstraZeneca; Roche
 
Qingyuan Zhang
No Relationships to Disclose
 
Nong Xu
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Zhanhui Miao
No Relationships to Disclose
 
Lin Shen
No Relationships to Disclose
 
Quanli Gao
No Relationships to Disclose
 
Zhidong Pei
No Relationships to Disclose
 
Teddy Xia
Employment - CStone Pharmaceuticals
Leadership - CStone Pharmaceuticals
Stock and Other Ownership Interests - CStone Pharmaceuticals
Honoraria - CStone Pharmaceuticals
 
Jingru Wang
Employment - CStone Pharmaceuticals
 
Hangjun Dai
Employment - CStone Pharmaceuticals
Stock and Other Ownership Interests - CStone Pharmaceuticals
Honoraria - CStone Pharmaceuticals
 
Rong Guo
Employment - CStone Pharmaceuticals
 
Jianxin Yang
Employment - CStone Pharmaceuticals
Leadership - CStone Pharmaceuticals
Stock and Other Ownership Interests - CStone Pharmaceuticals
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)